Teaser This review presents a systematic analysis on methods employed for assessing acceptability of oral medicines in children and older adults, to provide insights and recommendations regarding the design of reliable instruments in future studies.
Introduction
Global regulatory initiatives are fostering the development of patient-centric pharmaceutical products that accommodate the needs of all users, including children, older adults and their caregivers. The lack of suitable formulations for children and older patients is increasingly acknowledged by the regulatory and scientific communities given the prevalence of unlicensed and off-label medicine use, undocumented modifications of dosage forms, patient-reported administration difficulties and rates of non-adherence [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . In addition to being burdensome to patients and their caregivers, these practices can be detrimental to the safety and efficacy of medicines [11] [12] [13] [14] . As an example, tablets are often subdivided (split) into smaller segments to aid swallowing or to acquire a more suitable dose; however, this might be inappropriate for certain drug products. For example, subdivision of a tablet could lead to unequal segments with nonuniform drug doses [15] [16] [17] [18] . When a whole tablet has been coated with an enteric or modified release coating, breaking the tablet could compromise the functionality of the coating and hence alter bioavailability.
The European Medicines Agency (EMA) and Food and Drug Administration (FDA) have adopted legislations to promote the timely development and authorisation of medicines for use in children (between birth and 16 years in the USA and up to 18 years in Europe) [19] [20] [21] [22] . To support this, the EMA released a reflection paper in 2005 broadly outlining factors to be considered in the development of formulations for children [23] . As knowledge, opinion and experience in the field developed, the agency issued another guideline in 2014 further capturing considerations in the development of age-appropriate paediatric medicines [24] . At present, a draft reflection paper on the pharmaceutical development of medicines for use in the older people (defined as adults from 65 years of age) has also been released for public consultation [25] . Although not exhaustive, these documents emphasise the importance of recognising the distinct needs of children and older adults when designing drug products.
Particular emphasis is placed on establishing 'patient acceptability' of pharmaceutical products, defined as: 'the ability and willingness of a patient to use and its caregiver to administer the medicine as intended' [24, 25] . Ensuring that formulations are suitably designed and acceptable to end-users reduces the risks that medicine quality could be compromised, supports patient adherence and consequently leads to safer and effective use of medicines [9, 10] . Acceptability is influenced by factors related to pharmaceutical product design (such as route of administration, dosage form design, dosing frequency and features of administration and product packaging), as well as the characteristics of endusers [26, 27] . A patient's ability to use formulations as intended can vary, and is often dependent on several physiological, physical and psychological factors. Physiological functions and cognitive and motor skills inherently develop and mature from birth to adulthood. At the other end of the spectrum, aging is characterised by the decline and deterioration in the functional capacity of organs, with elderly patients often presenting with physical and cognitive impairments, multiple comorbidities, polypharmacy and frailty [28] . As such, development of medicines suitable for use in children and older patients raises unique and related challenges around drug disposition, safety of excipients and limitations with practical usability of dosage forms. In both populations, caregivers often play an important part in facilitating the administration or management of medicines -in children before they can be given responsibility for their own medication intake and in older people if they become unable to manage their medicines. Collectively, these aspects increase the complexity of patientcentric pharmaceutical product design.
The lack of empirical evidence on suitability and end-user opinions of pharmaceutical formulations across both populations is well documented [29] [30] [31] . Consequently, the current EMA guidelines advocate that patient acceptability is evaluated as an integral part of pharmaceutical and clinical development [24] , and over the product lifecycle [25] . Ideally, this pivotal data should be sought from patients and caregivers themselves as a fundamental outcome of well-designed clinical studies with the proposed medicine. Alternative sources could provide indications of adequate patient acceptability, such as human factor studies with patients or healthy volunteers, using existing clinical trial data, or market experiences and literature reports [8, [32] [33] [34] . However, knowledge regarding suitable methodologies for testing acceptability is sparse and fragmented, and a harmonised approach between industry and regulators is lacking [35] . Recent reviews have presented literature evidence of acceptability of pharmaceutical formulations in children and older patients [29] [30] [31] . This review aims to identify studies reporting on formulation aspects of oral medications that have been shown to influence their acceptability in paediatric and older populations, with a specific emphasis on the evaluation of the methodological approaches to provide insights and recommendations to the design of reliable instruments in future studies.
Methods

Search strategy
Indexed publications were identified by searching three electronic databases: Pubmed, Scopus and Embase, with coverage from the start date to May 2017 for all sources. The search strategy combined Boolean operators ('AND') using any of the search terms shown in Table 1 . In addition, a manual search of references within publications included from the electronic search was conducted to complement the electronic search. Literature collections from expert members of the European Paediatric Formulation Initiative (EuPFI) were also reviewed.
Selection criteria
Four reviewers (F.L., S.R.R., F.L.L. and F.R.) independently conducted initial screens of identified abstracts and titles. Abstracts were excluded if they were not in the English language, did not report original data (e.g., review papers) or were duplicates. Articles were included in the review if the age of the study population was in the ranges between 0 and 18 years and >60 years. Although the WHO has used the chronological age of 65 years as the definition of 'an older or elderly person' [36], historically 60 years of age has been applied as the cut-off age for 'older population' or 'geriatrics' and was therefore adopted in the inclusion criteria of this review. Where a study had a population with a mixture of age ranges, the study was included if (i) the mean/median age was between 0 and 18 years or >60 years, (ii) separate results were presented for age groups of 0-18 years old or >60 years old, or (iii) >50% of participants were between 0 and 18 years or >60 years old.
Studies were included if patient acceptability of an oral formulation was evaluated, as defined by the EMA as 'an overall ability of the patient and caregiver (defined as 'user') to use a medicinal product as intended (or authorised)' [24, 25] . Assessments included measures of swallowability (the capacity to ingest an oral formulation upon administration into the oral cavity) [25] and key organoleptic properties such as shape, size, colour, texture and palatability. Because this review focuses on the pharmaceutical formulation itself, studies evaluating aspects such as packaging, medicine administration devices and the impact of dosing frequency were not included. Studies that solely focused on taste assessment or taste comparisons of different formulations were also excluded because this has been reviewed elsewhere [37, 38] . However, studies were included if taste assessment was part of the overall acceptability evaluation of the formulation. Evaluation of medicine adherence (or compliance) applies different definitions and assessment methods to acceptability [39] and studies solely investigating these outcomes were also excluded. Disagreements about the eligibility of studies were resolved by consensus, including, where necessary, with the input of additional reviewers.
Data extraction
Data were extracted by each reviewer into structured summary tables and cross-checked for accuracy. Discrepancies were resolved by consensus, including, where necessary, with the input of additional reviewers. Key details extracted for each study included formulation characteristics (e.g., dosage form type, size, shape and drug content), participant age and health condition, reporting persons (i.e., self-report or report by caregivers or observers), sample size, study setting (country location and data collection setting), design and acceptability assessment and primary outcomes.
Results
The electronic search identified 2590 records potentially eligible for inclusion (Fig. 1) . Following a manual screening of titles, abstracts and full-texts, 44 publications were eligible for inclusion. An additional 24 papers were included after manual screening of references within eligible publications and through studies identified by the expert panel. Therefore, a total of 68 publications were included for analysis. The characteristics of the included studies are summarised in Table 2 . A total of 51 (75%) publications were paediatric-population-based studies and 17 (25%) were based on the older population. The earliest study identified was published in 1987, whereas 42 articles (62% of the combined total) were published in the past decade from 2007 to 2017, showing increasing research intensity in this area. Sixty studies (88% of the combined total) were conducted in European and Northern American countries. Tables 3 and 4 summarise the methodology and outcomes of each eligible study with regards to the acceptability assessment. Thirty studies (44%) assessed the acceptability of one single type of oral dosage form, for example tablets, capsules or suspensions (Table 3) , whereas the remaining studies (n = 38, 56%) evaluated or compared more than one type of dosage form, for example the acceptability or preference of tablet versus oral suspension (Table  4 ). For paediatric-based studies (n = 51), the individual who provided the responses to the acceptability assessment included children (n = 21, 41% of the total paediatric studies), caregivers including parents and carers (n = 19, 37% of the total paediatric studies), children and caregivers (n = 10, 20% of the total paediatric studies) and observers or investigators (n = 1, 2% of total paediatric studies). Thirty-five percent (24/68) of the studies evaluated the acceptability of medicines already being prescribed to the patients, whereas in the rest of the studies (65%) patients received medicines for the purpose of testing their acceptability.
Further details on the methodology directly related to the acceptability assessment were extracted and are listed in Table  5 . Questionnaires (n = 41, 60%) were the most commonly applied method in assessing acceptability of formulations, followed by observations (n = 16, 24%) that mostly related to observing the ability of the participant to swallow oral formulations. A variety of terms were used to describe or measure the acceptability (Table 5) ; 'acceptability' was the most commonly used term (n = 17, 25%) followed by 'preference' (n = 13, 19%). More than one-third of the studies (n = 26, 38%) lacked a clear definition on acceptability or other synonymous terms used. It is noteworthy that no studies included in the analysis provided standardised criteria for acceptability assessment, for example the 'acceptability rate' or the minimum % rate that would deem the formulation to be considered acceptable to patients.
Discussion
Study types and settings
In assessing formulation aspects of oral medications that influence their acceptability in the paediatric and older populations, this review examined 68 studies with 51 paediatric-and 17 olderpopulation-based studies. Evident from examining these studies is the lack of standardisation in study design and the assessment methods used. Table 6 summarises study design considerations for dosage form acceptability assessments in children and older adults. All aspects of study design differ considerably in the reviewed studies. The types of the studies include clinical trials evaluating efficacy and tolerability of treatments, standalone investigations into acceptability of medicines such as post-marketing surveys and swallowability evaluation of solid dosage forms [3, 8, 34, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] (Table 2 ). The settings where the studies took place ranged from hospitals and specialised clinics to community-based environments (e.g., home, school, community centres) ( Table 2 ). It is acknowledged that patient acceptability is influenced not only by formulation attributes but also characteristics of the patient (e. g., disease type and stage). In this regard, acceptability studies performed in the targeted patient population during prospective studies such as clinical trials and observational studies in postmarketing surveys could provide a more representative insight into the true acceptability of the formulation compared with studies conducted in healthy volunteers. However, it should be noted there could potentially be a selection bias in clinical trials because only patients who are willing to participate are included. In addition, in studies nested to clinical trials, it can be difficult to deconvolute the effect of the dosage form design from the effect of the efficacy or safety balance of the medicine (e.g., appearance of adverse events). Although clinical trials are often conducted in standardised conditions, the translation of the outcomes to patients taking the medicines at home or at school might not be straight forward. Studies conducted in healthy subjects using placebo formulations can provide fundamental understanding of the acceptability of different dosage form designs. Equally, it might not be possible to generalise acceptability findings of a formulation, for example swallowability of a certain dosage form in a certain patient group, to other settings and patient groups because it can be influenced by the environment and the characteristics of the patient. For example, a substantial discrepancy in the prevalence of dysphagia symptoms between older patients in nursing homes (68%) and community-dwelling older adults has been found (11%) [73, 74] .
Participant characteristics
The participant characteristics varied in terms of age, disease status, developmental stages and/or age-related impairments in the reviewed studies. Age is often used in the classification of the paediatric and older populations. Although guidance is available to define paediatric subgroups according to age (ICH E11), this was not followed by the majority of paediatric-based studies with a wide variety of age ranges used, for example 0-26 years in one study [75] and 6 months to 14 years in another [76] . Although arbitrary age was suggested to be used to divide subgroups of the older population, numerical age alone scarcely correlates with physiological functions of the older individual or outcomes of interventions. Classification of the frailty status of older patients was proposed to be a more accurate reflection of physiological activities and abilities [77] . Healthy volunteers and patients with a range of diseases were recruited into these studies (Tables 2-4) . Disease conditions, especially the presence of multiple morbidities in the older patient, might affect the experience and acceptance of patients to take their medicines. Similar effects might be seen from patients' past experiences in taking medicines and the nature of 
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Reviews KEYNOTE REVIEW their current medications (including the likeliness of polypharmacy in the older patient). For instance, differences were reported in the preference of tablet colours between older patients taking small and large numbers (>10) of tablets each day [78] . To add to the complexity, variations in children's development and agerelated impairments in the older population (e.g., visual, cognitive and motoric functions) could also affect patient handling and taking their medicines.
Study methods and tools
The selection of the applied study methods and tools reflected the purpose of the studies. For example, assessing the swallowability of tablets and capsules was often done by direct observation or instrumental examination (e.g., videoendoscopy), whereas general acceptability of a formulation or medicine was conducted by interviews and questionnaires accompanied by facial and visual analogue scales (Tables 3 and 4) . Age-appropriate facial scales have been developed for taste assessment in paediatrics and can be adapted for acceptability studies [37] , although careful consideration must be given to the choice of scales and response options to avoid bias [79] . Two studies have used multiple endpoints to report the acceptability; for example, using the combination of children and parent reporting on acceptability and direct observation on the outcome of the intake [41, 80] . These combinations of endpoints might minimise the bias of using one method for reporting the acceptability. In the majority of the studies (65%), patients received medicines or placebo formulations for the purposes of assessing their acceptability and a smaller proportion of studies (35%) evaluated acceptability of medicines that have already been prescribed to the patients. Although using patients' own medicines gives a real-world judgement on the use of the medicines, it is necessary to conduct perspective studies such as randomised trials to compare the acceptability of newer types of medicines or formulations to conventional ones.
With regards to methodological details, differences were observed between studies in terms of number of participants, study duration, number of administration attempts and who was responsible for answering the questions. In paediatric-based studies, feedback on acceptability or otherwise of the formulations was given almost equally by the children and their parents or caregivers (Tables 3 and 4) . However, it is interesting to note that in certain studies caregiver or parental response was used for children older than 12 years (up to 26 years old) [34, 75, 81] . In most of the older-population-based studies, acceptability was evaluated by the patients themselves, with the exceptions of caregivers' satisfaction for medicines used in the treatment of Alzheimer's and Parkinson's diseases. This was probably because of the disease-related decline in patients' capacity in participating in the studies [82, 83] . However, the acceptability of the patient might differ from that reported by caregivers.
Clarification is required regarding circumstances under which the caregiver's (parent's or partner's) response should be used instead of the patient's in the paediatric and older populations. FDA guidance on patient-reported outcome (PRO) measures could provide some valid insight into this question [22] . This guidance highlights the challenge of PROs in children and in patients who have cognitive impairment or are unable to communicate. For these populations, especially patients who cannot respond for themselves, the FDA encourages observer reports that include only those events or behaviours that can be observed, and discourages proxy-reported outcome measures. As an extension of this guidance, in 2013 an International Society for Pharmacoeconomics and Outcomes Research (ISPOR) taskforce proposed good practices for paediatric PRO research, which is conducted to inform regulatory decision-making and support claims made in medical product labelling [84] . These recommendations propose that there is no clear evidence of child-report reliability and validity in children aged below 5 years. Between the ages of five and seven, responses are questionable but their validity improves between 8-11 years of age. This taskforce considered that self-reports should be preferred only for children older than 11 years. In addition, the ASTM 'Standard Guide for Sensory Evaluation of Products by Children', although developed for food products, provides guidance on the development of studies in children of different ages [85] . The EMA has also expressed a view that it is preferable for acceptability studies to be conducted in the most relevant patient population as an integrated part of clinical trials [24, 26] .
Acceptability definitions and criteria
Although attempts were made to evaluate acceptability of dosage forms in the two patient populations, a common definition of acceptability was not applied in the studies. In several studies, terms such as 'acceptability', 'ease of administration', 'ease of use', 'preference', 'ability in swallowing', 'ease of swallowing', 'problems in administering tablet' and 'success in swallowing pills' were used as the evaluation for the success or otherwise of the study without clear definition of these terms (Table 6) . 'Acceptability' has been defined in recent guidelines [24, 25] , which has been a key step forward in improving the understanding in acceptability testing as researchers start designing their studies to explore the ability and willingness of the patients to take their medicine as intended. In other words, the definition enables researchers to identify and focus to achieve the same aim. Recent reviews have proposed specific definitions of the terms relevant to acceptability such as preference and usability [29] . However, it needs to be noted that these terms differ from the regulatory definitions of 'acceptability'. For example, 'preference' is not used as a part of the terminology in regulatory guidelines. Patient preference of one medicine over another gives only the relative comparison and not the actual acceptability of the medicine. Overall acceptability is the combined effect of several contributing factors such as appearance, palatability, swallowability and ease of administration [26] . Consequently, the definition of acceptability is open to interpretation and the way it is translated into practice might differ between studies (i.e., different outcome measures and data collection tools). There is a need for a stream of work to harmonise the study design as well as the collection and analysis of data to be able to compare the outcomes of different studies.
A first attempt to consider simultaneously the contributing factors of acceptability has been described recently [86] , whereby acceptability has been approached as a multidimensional concept. An acceptability reference framework, map and profiles have been designed using evaluations of medicine use in real-life conditions. For each evaluation, a set of contributing factors has been observed and the data have been treated with multiple correspondence analysis to define an acceptability map. Utilising a clustering process, evaluations reflecting treatments positively accepted emerged in a different cluster than those that were negatively accepted. The first results showed that in 70% of the treatment evaluations performed the medicines were positively accepted (234 children, 109 medicines) [86] . A further larger scale application of the tool showed similar results with 72% positive acceptability in 850 children and 80% positive acceptability in 950 older patients (unpublished data from F.R.). The reliability of the model has been validated in a paediatric population [87] .
Other tools might be considered in adaptation for acceptability assessment, such as the Medication Acceptance Scale (MAS) which evaluates a child's reaction to medication based on facial expressions, reactions upon ingestion and amount of dose swallowed [88] . This tool could be useful for patients with difficulties using scales (e.g., young children, older patients with certain diseases). However, it needs to be noted that the MAS has been specifically designed for infants and certain items (e.g., crying and body movement or level of agitation) might not be suitable for other populations such as older patients. In the studies analysed in this review, Rodd et al. modified the MAS by deleting the section regarding gross motor movements and the authors stated that ''it was not deemed appropriate for newborns" [89] . Other tools used in PRO measures include the Treatment Satisfaction Questionnaire for Medication (TSQM) [90] , Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) [91] and ACCEPT [92] and those recommended by the Equator Network (http://www. equator-network.org/reporting-guidelines/), which could be considered for adaptation in acceptability assessment. However, these PRO instruments are proposed to assess 'satisfaction', which includes other factors of interest (e.g., side effects, symptom relief and effectiveness) other than acceptability of the formulation. Moreover, these tools have been validated in adult populations and their appropriateness for use in children (especially aged under 12 years) and older patients needs to be carefully evaluated. Correspondingly, the criteria used for determining whether or not a formulation is acceptable is missing from the studies. Again, a universally agreed arbitrary limit or standard (e.g., 70% or 80% acceptance) might be considered; however, in certain circumstances a risk:benefit-based approach might be more appropriate on a case-by-case basis. One solution would be to join the efforts of key stakeholders to prepare a reporting guideline for medicine acceptability testing as for other main study types such as observational studies and randomised trials. The standardisation of study methodology and data reporting will assist researchers to publish high-impact health research and generate evidence-based information towards better medicines for children and older people. It is to be acknowledged that scientific publications could be used as supportive evidence in the approval of new medicines, although regulatory bodies might still require the original data to be submitted and reviewed as part of regulatory procedures.
Limitations of the study
This review has focused only on formulation aspects of the pharmaceutical product design and does not include other aspects such as packaging or device used. It should be acknowledged that aspects of a medicinal product other than formulation also have profound impacts on patient acceptability, as shown by Drumond et al. [29] . Data extraction did not consider the effects of the study settings, such as the presence of caregivers or the researcher or observer on the outcome measures on acceptability. However, this might change the behaviour of the child or older patient and alter the overall acceptability results.
Concluding remarks
The development of medicines that are appropriate and acceptable to paediatric and older patients is of paramount importance in ensuring adherence and medication safety [93] . However, assessing the acceptability of medicines in these patient groups is challenging, considering the complexity of the study population and the diversity of the end goal of the individual investigation. Published methods reporting acceptability of oral medicines in children and older adults show a lack of standardisation in terms of participant characteristics, the study settings, evaluation tools and endpoint criteria. A consensus agreement between academia, the pharmaceutical industry and regulators would be welcomed to harmonise and standardise the methodology for acceptability assessment of pharmaceutical products.
